AtaGenix Laboratories
AtaGenix Laboratories
Release time: 2026-03-23 View volume: 2
Antibody humanization reduces immunogenicity of non-human antibodies for therapeutic use by replacing animal-derived framework regions with human sequences while retaining antigen-binding specificity. This guide covers the main methods, when humanization is needed, and what to expect from a humanization project.
Antibodies discovered in mice, rats, or rabbits contain non-human framework sequences that the human immune system can recognize as foreign, triggering anti-drug antibody (ADA) responses that reduce efficacy and cause adverse effects. Humanization replaces animal framework regions with human germline sequences, keeping the complementarity-determining regions (CDRs) that define antigen binding. The result is a molecule that looks human to the immune system but retains the binding properties of the original animal antibody.
| Method | Principle | Pros | Cons |
|---|---|---|---|
| CDR Grafting | Transplant CDRs from animal antibody onto human framework | Most established; high humanness score | May lose affinity; back-mutations often needed |
| SDR Grafting | Transplant only specificity-determining residues (subset of CDR) | Higher humanness than CDR grafting | Requires accurate identification of key contact residues |
| Framework Shuffling | Combine CDRs with a library of human frameworks; screen for best binders | Explores more framework options | Requires screening; more time-intensive |
| Resurfacing (Veneering) | Replace only surface-exposed residues with human equivalents | Minimal structural disruption | Lower humanness than full CDR grafting |
Therapeutic development: Required for any antibody intended for repeated human dosing to minimize ADA responses.
Not needed for research-only use: If the antibody is used only as a lab reagent (WB, IHC, ELISA), humanization is unnecessary.
Consider chimerization first: If timeline or budget is limited, a chimeric antibody (animal V regions + human constant regions) can serve as an interim step before full humanization.
Typically 3–6 humanized variants are designed and expressed in parallel, then screened by ELISA and SPR to identify candidates retaining parental affinity (≥80% of original KD) with high humanness scores. AtaGenix supports the full workflow from sequence analysis through recombinant expression and functional validation.
Have a mouse or rabbit lead antibody that needs humanization for therapeutic development? AtaGenix provides CDR grafting, variant design, and recombinant expression with SPR affinity validation.
Talk to Technical SupportResponse within 24 hours
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
